ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Utilizing its proprietary protein engineering platform, ProMIS specializes in the identification and targeting of misfolded proteins associated with these diseases, which enhances the safety and efficacy of its drug candidates. The company boasts a robust and diverse pipeline of candidates in various stages of development, positioning it favorably to address significant unmet medical needs in the biopharmaceutical arena, making it a compelling investment opportunity for institutional investors seeking growth in the healthcare sector.
| Revenue (TTM) | 7,560 |
| Gross Profit (TTM) | $-33.38M |
| EBITDA | $-13.31M |
| Operating Margin | 0.00% |
| Return on Equity | -115.70% |
| Return on Assets | -63.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.77 |
| Price-to-Book | 2.01 |
| Price-to-Sales (TTM) | 4016.22 |
| EV/Revenue | 4004.98 |
| EV/EBITDA | -1.74 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.97M |
| Float | $4.60M |
| % Insiders | 11.85% |
| % Institutions | 74.37% |
Volatility is currently expanding
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Promis Neurosciences (PMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in Promis Neurosciences (PMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.
Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update.
